免疫检查点抑制剂联合治疗肝癌的进展

免疫检查点抑制剂(ICI)治疗不可切除性肝癌近年来受到国内外研究者的极大关注,取得重大进展,但ICI单药治疗并不能使大多数肝癌患者受益。因此,探讨ICI联合其他治疗方法成为新的研究趋势。归纳了近些年国内外关于不可切除性肝癌ICI联合治疗相关进展,包括了联合分子靶向治疗、PD-1/PD-L1抑制剂联合CTLA-4抑制剂及联合局部治疗。分析表明,对于不可切除性肝癌患者,ICI联合其他治疗方法明显优于ICI单药治疗,但联合何种治疗方式能够使患者获益程度最佳,仍需进一步探索。

Advances in immune checkpoint inhibitor combined with other treatment methods for hepatocellular carcinoma

In recent years,immune checkpoint inhibitor(ICI)in the treatment of unresectable liver cancer has attracted great attention in China and foreign countries and great progress has been achieved,but ICI monotherapy cannot bring benefits to most patients with liver cancer.Therefore,it is a new trend to explore the combination of ICI with other treatment methods.This article summarizes the advances in ICI combination therapy for unresectable liver cancer in China and foreign countries,including ICI combined with molecular targeted therapy,PD-1/PD-L1 inhibitor combined with CTLA-4 inhibitor,and ICI combined with local therapy.The results show that for patients with unresectable liver cancer,ICI combined with other treatment methods has a significantly better effect than ICI monotherapy;however,further studies are needed to explore which treatment method combined with ICI can bring the greatest benefits to patients.